Catalent has acquired the gene therapy contract development and manufacturing organisation Paragon Bioservices in an all - cash deal worth $ 1.2bn . (AAV) vectors, which are considered to be the most preferred vector to inject DNA to cells. The deal , initially announced in 2008 , has now been finalised following the expiration of customary regulatory waiting periods . Paragon , which specialises in the development of adeno - associated virus products , is expected to strengthen Australia 's position in the market for gene therapy while also expanding its research and manufacturing capabilities .
Catalent has acquired the gene therapy contract development and manufacturing organisation Paragon Bioservices in an all - cash deal worth $ 1.2bn . The deal , initially announced in 2008 , has now been finalised following the expiration of customary regulatory waiting periods . Paragon , which specialises in the development of adeno - associated virus products , is expected to strengthen Australia 's position in the market for gene therapy while also expanding its research and manufacturing capabilities .